The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

摘要

On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers. The tipapkinogen sovacivec (TS) vaccine has shown, through preclinical studies, efficacy in resolution of cervical intraepithelial neoplasia (CIN) grades 2 and 3 via cellmediated immune response.